Business Context and Reporting Period
This Form 8-K filing by Disc Medicine, Inc. (IRON) reports a corporate event with a report date of September 28, 2023. The company is incorporated in Delaware and trades on The Nasdaq Global Market. The filing specifically addresses the termination of a material definitive agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative termination of a sales agreement rather than reporting periodic financial results.
Material Changes
- Termination of Sales Agreement: On September 20, 2023, the Company notified Leerink Partners LLC of its intent to terminate the Sales Agreement dated January 25, 2023. The termination became effective on September 28, 2023.
- Previous Suspension: The Company had previously suspended the offering of common stock under this agreement on June 12, 2023. No sales were made following this suspension date.
- Financial Impact: The Company confirmed it is not subject to any termination penalties related to this action.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks beyond the conclusion of the terminated agreement. The document serves as a notification of the completed termination process.
Key Facts for Investor Verification
- Verify the effective date of the termination (September 28, 2023) and the absence of termination penalties.
- Confirm that no shares were sold under the Sales Agreement after the June 12, 2023 suspension.
- Review the original Sales Agreement filed as Exhibit 1.1 to the January 25, 2023 Form 8-K for historical context.